• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国慢性阻塞性肺疾病的照护级联:一项针对国家“快乐呼吸”项目入组时个体水平数据的横断面研究。

The care cascade of chronic obstructive pulmonary disease in China: a cross-sectional study of individual-level data at enrolment into the national 'Happy Breathing' Programme.

作者信息

Wang Chen, Qi Weiran, Yang Ting, Jiao Lirui, Chen Qiushi, Huang Ke, Yu Fengyun, Geldsetzer Pascal, Bärnighausen Till, Chen Simiao

机构信息

School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

National Clinical Research Center for Respiratory Diseases, Beijing, China.

出版信息

EClinicalMedicine. 2024 Jul 16;74:102597. doi: 10.1016/j.eclinm.2024.102597. eCollection 2024 Aug.

DOI:10.1016/j.eclinm.2024.102597
PMID:39114273
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11305216/
Abstract

BACKGROUND

Understanding the chronic obstructive pulmonary disease (COPD) care cascade is crucial for identifying where and when to intervene to improve COPD outcomes. We aimed to determine the proportion of patients with COPD seeking care in China's health system who are lost at each stage of the COPD care cascade and how the patterns of loss vary across geographical regions and population groups.

METHODS

From November 3, 2018, to April 22, 2021, we used individual-level patient data from the national Chinese 'Happy Breathing' Programme, which aims to identify patients with COPD and provide appropriate care. COPD was defined as a post-bronchodilator ratio of forced expiratory volume in 1 s to forced vital capacity (FEV1/FVC) <0.70. We calculated the proportions of individuals who, at enrolment into the 'Happy Breathing' Programme, (i) had ever undergone a pulmonary function test, (ii) had been diagnosed with COPD in the past, (iii) were currently on treatment for COPD, and (iv) had achieved control of their COPD. We examined the association between reaching each stage of the care cascade and individual patient characteristics as well as regional-level economic development and available resources in the health system using multilevel regression.

FINDINGS

Among the 29,201 patients with COPD in the 'Happy Breathing' Programme, 41.0% (95% confidence interval [CI]: 40.4-41.6%) had ever been tested for COPD, 17.6% (95% CI: 17.1-18.0%) had previously been diagnosed with COPD, 8.5% (95% CI: 8.2-8.8%) were currently on treatment for COPD, 4.6% (95% CI: 4.3-4.8%) of patients had mild or no exacerbations in the prior year, and 3.9% (95% CI: 3.7-4.2%) of patients had suffered no exacerbations in the prior year. On average, patients living in the cities of Beijing, Wuhan, and Yinchuan had progressed further along the COPD care cascade than patients living in Daqing and Luoyang. Using multilevel regression, we found that young age, rural residence, and low regional per-capita GDP were significantly associated with larger losses at each stage of the COPD care cascade.

INTERPRETATION

Substantial proportions of patients with COPD are lost at each stage of the COPD care cascade in the Chinese health system. The largest losses occur during the initial stages of the cascade, when diagnosis first occurs. New policies and interventions are required to boost COPD care, especially screening and diagnosis, in the Chinese health system to reduce this large disease burden.

FUNDING

This work was supported by Major Programme of National Natural Science Foundation of China (82090011), CAMS Innovation Fund for Medical Sciences (CIFMS) (2021-I2M-1-049), and Horizon Europe (HORIZON-MSCA-2021-SE-01; project number 101086139-PoPMeD-SuSDeV). TB was supported by the Alexander von Humboldt Foundation through the Alexander von Humboldt professorship award.

摘要

背景

了解慢性阻塞性肺疾病(COPD)护理流程对于确定在何处以及何时进行干预以改善COPD治疗效果至关重要。我们旨在确定在中国卫生系统中寻求治疗的COPD患者在COPD护理流程各阶段流失的比例,以及流失模式在不同地理区域和人群中的差异。

方法

从2018年11月3日至2021年4月22日,我们使用了中国全国性“快乐呼吸”项目的个体层面患者数据,该项目旨在识别COPD患者并提供适当护理。COPD被定义为支气管扩张剂使用后1秒用力呼气容积与用力肺活量的比值(FEV1/FVC)<0.70。我们计算了在加入“快乐呼吸”项目时,(i)曾进行过肺功能测试、(ii)过去曾被诊断为COPD、(iii)目前正在接受COPD治疗、以及(iv)COPD已得到控制的个体比例。我们使用多水平回归分析了达到护理流程各阶段与个体患者特征以及地区层面经济发展和卫生系统可用资源之间的关联。

结果

在“快乐呼吸”项目的29201例COPD患者中,41.0%(95%置信区间[CI]:40.4 - 41.6%)曾接受过COPD检测,17.6%(95%CI:17.1 - 18.0%)过去曾被诊断为COPD,8.5%(95%CI:8.2 - 8.8%)目前正在接受COPD治疗,4.6%(95%CI:4.3 - 4.8%)的患者上一年轻度发作或未发作,3.9%(95%CI:3.7 - 4.2%)的患者上一年未发作。平均而言,居住在北京、武汉和银川市的患者在COPD护理流程中的进展比居住在大庆和洛阳的患者更大。使用多水平回归分析,我们发现年轻、农村居住以及地区人均GDP较低与COPD护理流程各阶段的更大流失显著相关。

解读

在中国卫生系统中,相当比例的COPD患者在COPD护理流程的各阶段流失。最大的流失发生在流程的初始阶段,即首次诊断时。需要新的政策和干预措施来加强中国卫生系统中的COPD护理,特别是筛查和诊断,以减轻这一巨大的疾病负担。

资金来源

本研究得到了中国国家自然科学基金重大项目(82090011)、中国医学科学院医学创新基金(CIFMS)(2021 - I2M - 1 - 049)以及欧洲地平线计划(HORIZON - MSCA - 2021 - SE - 01;项目编号101086139 - PoPMeD - SuSDeV)的支持。TB得到了亚历山大·冯·洪堡基金会通过亚历山大·冯·洪堡教授奖提供的支持。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/11305216/e186262f8a15/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/11305216/d4f4cf979588/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/11305216/30604f4d75b9/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/11305216/6be15b0d5cf4/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/11305216/abfea5fdfc83/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/11305216/e186262f8a15/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/11305216/d4f4cf979588/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/11305216/30604f4d75b9/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/11305216/6be15b0d5cf4/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/11305216/abfea5fdfc83/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/11305216/e186262f8a15/gr5.jpg

相似文献

1
The care cascade of chronic obstructive pulmonary disease in China: a cross-sectional study of individual-level data at enrolment into the national 'Happy Breathing' Programme.中国慢性阻塞性肺疾病的照护级联:一项针对国家“快乐呼吸”项目入组时个体水平数据的横断面研究。
EClinicalMedicine. 2024 Jul 16;74:102597. doi: 10.1016/j.eclinm.2024.102597. eCollection 2024 Aug.
2
Cost-effectiveness of population-based screening for chronic obstructive pulmonary disease in China: a simulation modeling study.中国基于人群的慢性阻塞性肺疾病筛查的成本效益:一项模拟建模研究
Lancet Reg Health West Pac. 2024 Apr 29;46:101065. doi: 10.1016/j.lanwpc.2024.101065. eCollection 2024 May.
3
The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020-50: a health-augmented macroeconomic modelling study.2020-50 年全球 204 个国家和地区慢性阻塞性肺疾病的全球经济负担:一项健康增强型宏观经济建模研究。
Lancet Glob Health. 2023 Aug;11(8):e1183-e1193. doi: 10.1016/S2214-109X(23)00217-6.
4
The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1·1 million adults.44 个低收入和中等收入国家的高血压护理状况:来自 110 万成年人的全国代表性个体水平数据的横断面研究。
Lancet. 2019 Aug 24;394(10199):652-662. doi: 10.1016/S0140-6736(19)30955-9. Epub 2019 Jul 18.
5
Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.低剂量茶碱口服联合吸入皮质激素治疗慢性阻塞性肺疾病且有加重高风险的患者:一项 RCT 研究。
Health Technol Assess. 2019 Jul;23(37):1-146. doi: 10.3310/hta23370.
6
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
7
Sociodemographic correlates with prevalence of comorbidities in patients with chronic obstructive pulmonary disease: a study from a Chinese National Survey.慢性阻塞性肺疾病患者合并症患病率的社会人口学相关因素:一项来自中国全国性调查的研究
Lancet Reg Health West Pac. 2023 Oct 13;42:100937. doi: 10.1016/j.lanwpc.2023.100937. eCollection 2024 Jan.
8
9
[Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].[氯化乙酰甲胆碱支气管激发试验标准技术规范(2023年)]
Zhonghua Jie He He Hu Xi Za Zhi. 2024 Feb 12;47(2):101-119. doi: 10.3760/cma.j.cn112147-20231019-00247.
10
Heterogeneities and impact profiles of early chronic obstructive pulmonary disease status: findings from the China Pulmonary Health Study.早期慢性阻塞性肺疾病状态的异质性及影响特征:中国肺部健康研究的结果
Lancet Reg Health West Pac. 2024 Feb 6;45:101021. doi: 10.1016/j.lanwpc.2024.101021. eCollection 2024 Apr.

引用本文的文献

1
Lung Health of Early COPD (LHEC): A Multi-Center Cohort Study-Rational and Design.早期慢性阻塞性肺疾病的肺部健康(LHEC):一项多中心队列研究——原理与设计
Int J Chron Obstruct Pulmon Dis. 2025 Jul 19;20:2561-2568. doi: 10.2147/COPD.S517185. eCollection 2025.
2
Burden of chronic obstructive pulmonary disease and risk factors in China from 1990 to 2021: Analysis of global burden of disease 2021.1990年至2021年中国慢性阻塞性肺疾病负担及危险因素:全球疾病负担研究2021分析
Chin Med J Pulm Crit Care Med. 2025 Jun 14;3(2):132-140. doi: 10.1016/j.pccm.2025.05.004. eCollection 2025 Jun.
3
Optimizing hypertension management in China: care cascade insights and individual determinants from a national survey.

本文引用的文献

1
The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020-50: a health-augmented macroeconomic modelling study.2020-50 年全球 204 个国家和地区慢性阻塞性肺疾病的全球经济负担:一项健康增强型宏观经济建模研究。
Lancet Glob Health. 2023 Aug;11(8):e1183-e1193. doi: 10.1016/S2214-109X(23)00217-6.
2
Health Literacy and Health Outcomes in Chronic Obstructive Pulmonary Disease Patients: An Explorative Study.健康素养与慢性阻塞性肺疾病患者健康结局的关系:一项探索性研究。
Front Public Health. 2022 Mar 17;10:846768. doi: 10.3389/fpubh.2022.846768. eCollection 2022.
3
Investigating primary healthcare practitioners' barriers and enablers to referral of patients with COPD to pulmonary rehabilitation: a mixed-methods study using the Theoretical Domains Framework.
优化中国高血压管理:基于全国调查的治疗流程见解与个体决定因素
Curr Med Res Opin. 2025 May;41(5):741-751. doi: 10.1080/03007995.2025.2502674. Epub 2025 Jun 5.
4
Cost-effectiveness of chronic obstructive pulmonary disease population screening in China: based on individual data from WHO Collaborating Centre-initiated 'Enjoying Breathing Program'.中国慢性阻塞性肺疾病人群筛查的成本效益:基于世界卫生组织合作中心发起的“畅享呼吸计划”的个体数据
BMC Public Health. 2025 Apr 24;25(1):1528. doi: 10.1186/s12889-025-22506-9.
5
Cost-effectiveness of population-based screening for chronic obstructive pulmonary disease in China: a simulation modeling study.中国基于人群的慢性阻塞性肺疾病筛查的成本效益:一项模拟建模研究
Lancet Reg Health West Pac. 2024 Apr 29;46:101065. doi: 10.1016/j.lanwpc.2024.101065. eCollection 2024 May.
调查初级保健从业者在将 COPD 患者转介至肺康复治疗方面的障碍和促进因素:使用理论领域框架的混合方法研究。
BMJ Open. 2022 Jan 19;12(1):e046875. doi: 10.1136/bmjopen-2020-046875.
4
Prevalence and Treatment of Diabetes in China, 2013-2018.中国糖尿病患病率及治疗状况 2013-2018 年
JAMA. 2021 Dec 28;326(24):2498-2506. doi: 10.1001/jama.2021.22208.
5
Trend of Mortality and Years of Life Lost Due to Chronic Obstructive Pulmonary Disease in China and Its Provinces, 2005-2020.中国及其省份 2005-2020 年慢性阻塞性肺疾病死亡率及寿命损失年趋势。
Int J Chron Obstruct Pulmon Dis. 2021 Oct 29;16:2973-2981. doi: 10.2147/COPD.S330792. eCollection 2021.
6
Strategies for the prevention, diagnosis and treatment of COPD in low- and middle- income countries: the importance of primary care.低收入和中等收入国家慢性阻塞性肺疾病的预防、诊断及治疗策略:初级保健的重要性
Expert Rev Respir Med. 2021 Dec;15(12):1563-1577. doi: 10.1080/17476348.2021.1985762. Epub 2021 Oct 12.
7
The role of the Basic Public Health Service program in the control of hypertension in China: Results from a cross-sectional health service interview survey.《基本公共卫生服务项目在我国高血压控制中的作用:一项基于卫生服务横断面访谈调查的研究结果》。
PLoS One. 2021 Jun 18;16(6):e0217185. doi: 10.1371/journal.pone.0217185. eCollection 2021.
8
Unmet needs as indicator of improving chronic care delivery system in China.未满足的需求作为中国改善慢性病护理服务体系的指标。
Chronic Dis Transl Med. 2020 Sep 4;7(1):1-13. doi: 10.1016/j.cdtm.2020.08.001. eCollection 2021 Mar.
9
Cascade of care for children and adolescents with chronic hepatitis C.儿童和青少年慢性丙型肝炎的治疗流程。
World J Gastroenterol. 2021 Mar 28;27(12):1117-1131. doi: 10.3748/wjg.v27.i12.1117.
10
[Guidelines for the diagnosis and management of chronic obstructive pulmonary disease (revised version 2021)].慢性阻塞性肺疾病诊断和管理指南(2021年修订版)
Zhonghua Jie He He Hu Xi Za Zhi. 2021 Mar 12;44(3):170-205. doi: 10.3760/cma.j.cn112147-20210109-00031.